Pharmacokinetic profile of valganciclovir in pediatric transplant recipients

Pediatric Infectious Disease Journal

Volumn 31, Issue 4, 2012, Pages 405-407

  Launay, Elise ^a   Théôret, Yves ^b   Litalien, Catherine ^a,b   Duval, Michel ^a   Alvarez, Fernando ^a   Lapeyraque, Anne Laure ^a,b   Phan, Veronique ^a   Larocque, Diane ^b   Poirier, Nancy ^a   Lamarre, Valerie ^a   Ovetchkine, Philippe ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

cytomegalovirus; ganciclovir; pediatrics; pharmacokinetics; valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG DOSAGE FORM COMPARISON; FEMALE; GRAFT RECIPIENT; HUMAN; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; GANCICLOVIR; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; PLASMA; TRANSPLANTATION;

EID: 84858800269     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182463a19     Document Type: Article

References (16)

1. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725-738. (Pubitemid 39574344)
2. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711-721.
3. Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother. 2002;36:1075-1079. (Pubitemid 34564394)
4. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation. 2006;82:30-35. (Pubitemid 44296974)
5. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:851-856.
6. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 2006;107:3002-3008.
7. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636-643.
8. Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis. 2010;12:195-203.
9. Kasiari M, Gikas E, Georgakakou S, et al. Selective and rapid liquid chromatography/negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;864:78-86.
10. Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986;40:281-286. (Pubitemid 16017854)
11. Zhang D, Lapeyraque AL, Popon M, et al. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol. 2003;18:943-948. (Pubitemid 37121631)
12. Food and Drug Administration. Valcyte (valganciclovir hydrochloride) label change: possible overdose in pediatric patients. Posted 2010/09/15. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm225888.htm. Accessed on October 8, 2010.
13. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477-1483. (Pubitemid 40847577)
14. Pescovitz MD, Jain A, Robson R, et al. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc. 2007;39:3111-3116. (Pubitemid 350251513)
15. Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter-and intrapatient variability of ganciclovir levels in children. Pediatr Transplant. 2007;11:301-305. (Pubitemid 46570151)
16. Autmizguine J, Théôret Y, Launay E, et al. Low systemic ganciclovir exposure and preemptive treatment failure of cytomegalovirus reactivation in a transplanted child. J Popul Ther Clin Pharmacol. 18:e257-e260.